Zobrazeno 1 - 10
of 126
pro vyhledávání: '"клопидогрел"'
Autor:
I.O. Grazhdankin, A.A. Prokhorikhin, V.I. Baystrukov, E.I. Kretov, A.M. Chernyavskiy, V.L. Lukinov
Publikováno v:
Патология кровообращения и кардиохирургия, Vol 27, Iss 4, Pp 64-76 (2023)
Цель. Оценить взаимосвязь полиморфизмов гена CYP2C19 и клинических исходов у пациентов после успешной реваскуляризации по поводу острого
Externí odkaz:
https://doaj.org/article/9e42a699cfed499e8ab0103fd59c99b4
Publikováno v:
Žurnal Grodnenskogo Gosudarstvennogo Medicinskogo Universiteta, Vol 21, Iss 4, Pp 352-363 (2023)
Цель исследования. Определение клинических и лабораторных факторов, влияющих на высокую и низкую остаточную реактивность тромбоцитов
Externí odkaz:
https://doaj.org/article/e5e8e4a866dd442a8af230a513ea1782
Autor:
V. V. Bykov, A. V. Bykova, V. I. Smolyakova, G. A. Chernysheva, O. I. Alyev, A. M. Anishenko, A. V. Sidekhmenova, S. A. Stankevich, V. A. Khazanov, A. I. Vengerovsky
Publikováno v:
Разработка и регистрация лекарственных средств, Vol 11, Iss 3, Pp 70-74 (2022)
Introduction. The article presents the results of studying the antithrombotic activity of a novel drug, a soluble guanylate cyclase stimulator (codename – GRS), in experimental models of arterial and venous thrombosis and thromboembolism.Aim. Study
Externí odkaz:
https://doaj.org/article/73066aff73f64847b8ebb1e630543e48
Autor:
O. O. Shakhmatova
Publikováno v:
Атеротромбоз, Vol 12, Iss 1, Pp 30-45 (2022)
Clopidogrel is the most studied P2Y12 receptor blocker and still has no alternative in a number of categories of ACS patients in whom ticagrelor or prasugrel have not been studied or their use is associated with an unacceptably high risk of bleeding.
Externí odkaz:
https://doaj.org/article/89835148cd1645c7b94ca5c728158c6e
Publikováno v:
Žurnal Grodnenskogo Gosudarstvennogo Medicinskogo Universiteta, Vol 20, Iss 2, Pp 152-158 (2022)
Цель исследования – оценить частоту встречаемости высокой остаточной реактивности тромбоцитов (ВОРТ) у пациентов с не-Q инфарктом миок
Externí odkaz:
https://doaj.org/article/3c5c63841fad48f08fa5dff7c0b486a1
Autor:
B. I. Kantemirova, E. A. Orlova, O. S. Polunina, E. N. Chernysheva, M. A. Abdullaev, D. A. Sychev
Publikováno v:
Фармация и фармакология (Пятигорск), Vol 8, Iss 6, Pp 392-404 (2021)
Cardiovascular diseases (CVDs) are the leading cause of disability and mortality worldwide. Increased thrombosis is the trigger point for the development of various CVDs and their complications, and therefore, therapy with P2Y12-receptor inhibitors i
Externí odkaz:
https://doaj.org/article/3edf8e6e2e43471e867095b7a06eadec
Autor:
E. P. Panchenko
Publikováno v:
Атеротромбоз, Vol 0, Iss 2, Pp 56-64 (2020)
The article presents an analytical review of the studies aimed at determining the optimal antithrombotic therapy in patients with atrial fibrillation undergoing elective or emergency percutaneous coronary intervention (PCI) due to the development of
Externí odkaz:
https://doaj.org/article/8da77d7de50048358117be7606523d9e
Autor:
Alexander A. Spasov, Aida F. Kucheryavenko, Ksenia A. Gaidukova, Maxim V. Chernikov, Olga N. Zhukovskaya
Publikováno v:
Фармация и фармакология (Пятигорск), Vol 8, Iss 2, Pp 78-85 (2020)
The aim of the study was to investigate antithrombogenic properties of compound RU-1144 with previously identified pronounced antiplatelet and antioxidant activities. The thrombosis induced by Ferric chloride (FeCl3) was carried out in rats’ caroti
Externí odkaz:
https://doaj.org/article/c0a7ad2a433448b59f793fd1bba325d6
Autor:
I. S. Yavelov
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 21, Iss 2 (2022)
Externí odkaz:
https://doaj.org/article/0a134cf55dd4424699436868c7e136ba
Autor:
I. S. Yavelov
Publikováno v:
Атеротромбоз, Vol 0, Iss 1, Pp 72-81 (2020)
In the article, a review is given of the facts that determined contemporary views of the role of clopidogrel in the treatment of acute coronary syndrome. The author described a history of the clinical studies of clopidogrel in acute coronary syndrome
Externí odkaz:
https://doaj.org/article/e77676a377ec42ddb94b0a0de736c15e